News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

Erste Human-Ergebnisse der Zusammenarbeit: https://www.globenewswire.com/news-release/2021/11/30/2342890/0/en/Australian-Biotech-EnGeneIC-Strikes-Landmark-Deal-with-Major-US-Biotech-ImmunityBio-for-COVID-19-Vaccine-and-Cancer-Treatment.html

Zusammenarbeit bekannt gegeben: https://www.bcm.edu/news/baylor-tch-and-immunitybio-collaborate-for-covid-19-vaccine-for-africa

PiperSandler 33rd Annual Healthcare Conference NOV 30 - DEC 2, 2021 https://ir.immunitybio.com/events/event-details/pipersandler-33rd-annual-healthcare-conference

Institutional Ownership and Shareholders Immunitybio Inc (US:IBRX) has 295 institutional owners and shareholders (aka shareholding pattern) that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 38,996,995 shares. Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, XBI - SPDR(R) S&P(R) Biotech ETF, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, IWM - iShares Russell 2000 ETF, Geode Capital Management, Llc, NAESX - Vanguard Small-Cap Index Fund Investor Shares, Northern Trust Corp, and Jpmorgan Chase & Co.

Videopräsentation zur Jefferies Healthcare Conference: https://immunitybio.com/jefferies-london-healthcare-conference/

T-Zellen kontrollieren Sars-CoV-2 Bei der Untersuchung stellten die Forscher fest, dass sich in 20 Blutproben erhöhte Werte bestimmter T-Zellen befanden. "Ich habe so etwas noch nie gesehen. Es ist wirklich überraschend, dass die T-Zellen eine Infektion so schnell kontrollieren können", wird Shane Crotty, Immunologe am La Jolla Institute for Immunology in Kalifornien, der nicht an der Forschung beteiligt war, bei "Nature" zitiert. Es scheint so zu sein, dass das Immunsystem dieser Menschen in der Lage ist, das Virus zu bekämpfen, bevor es sich festsetzen und weiterverbreiten kann. Ein solcher Vorgang wird in der Fachsprache als "abortive Infektion" bezeichnet. Die schnelle und effektive Abwehr könnte durch diese spezifischen T-Zellen, die auch als Gedächtniszellen bezeichnet werden, zustande kommen. Es könnte sein, dass das Immunsystem dieser Menschen bereits darauf vorbereitet war, die neue Krankheit zu bekämpfen, erklärt Leo Swadling vom University College London, der an der Studie beteiligt war, laut BBC. Die T-Zellen sind laut Forscher in der Lage, den Komplex aus mehreren Virus-Proteinen zu erkennen und zu bekämpfen, sodass die Vermehrung des Virus, der sogenannte Replikationskomplex, deaktiviert und damit völlig eingestellt wird. Die Forscher fanden diese T-Zellen nicht nur häufiger im Blut bei denjenigen, die keine Anzeichen für eine Infektion gezeigt hatten, sondern auch in Proben, die bereits vor der Pandemie genommen worden waren. Auszug aus: https://www.n-tv.de/22939523

ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines Second-generation vaccines that combine different advanced DNA, RNA, Protein, and Adjuvant components are critical to providing accessible, broad, and durable protection against current and future likely SARS-CoV-2 variants By adding self-amplifying self-adjuvating RNA (SASA-RNA), next-generation nano-lipid carriers, recombinant protein, and adjuvant vaccine technologies to ImmunityBio’s current adenovirus vector vaccine, the company offers one of the most comprehensive vaccine technology platforms Such combination approaches are already being studied in trials in South Africa, including the fully enrolled Phase 2 SISONKE Boost trial, which is studying ImmunityBio’s hAd 5 as a boost to the Janssen COVID-19 prime This vaccine consortium is designed to create a comprehensive technology platform to serve as a foundation for the large-scale manufacture of multiple vaccine vectors for pandemic preparedness and for the treatment of cancer https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-expands-vaccine-program-accelerate-use-mix-and-match?field_nir_news_date_value[min]=

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. grew its stake in ImmunityBio by 48.4% in the 2nd quarter. BlackRock Inc. now owns 5,273,157 shares of the company’s stock worth $75,300,000 after acquiring an additional 1,719,492 shares during the period. Glenmede Trust Co. NA purchased a new stake in ImmunityBio in the 1st quarter worth approximately $1,809,000. Goldman Sachs Group Inc. purchased a new stake in ImmunityBio in the 1st quarter worth approximately $1,926,000. Rhumbline Advisers grew its stake in ImmunityBio by 135.3% in the 2nd quarter. Rhumbline Advisers now owns 89,140 shares of the company’s stock worth $1,273,000 after acquiring an additional 51,249 shares during the period. Finally, Illinois Municipal Retirement Fund purchased a new stake in ImmunityBio in the 2nd quarter worth approximately $228,000. Hedge funds and other institutional investors own 50.38% of the company’s stock. Quelle: https://zolmax.com/investing/immunitybio-nasdaqibrx-raised-to-hold-at-zacks-investment-research/6508747.html

Sec Form 10Q veröffentlicht: "For the nine months ended September 30, 2021, we received net proceeds totaling $136.9 million from the issuance of 10,216,978 shares under the ATM, … As of September 30, 2021, we had $359.0 million available for future stock issuances under the ATM." Keine Rede vom BLA. https://quantisnow.com/insight/2003377?s=s